June 17, 2016
Cambridge, MA

A Note from the CEO

It has been an exciting and eventful year for Solid Biosciences. Since our last update in 2015, Solid has grown significantly, adding team members, entering into new collaborations and moving into larger offices that include our own laboratory. Through all of this growth, our mission and resolve to find treatments, and one day a cure, for Duchenne muscular dystrophy remains as strong as ever.

In November, we gained significant momentum for our Solid GT gene therapy program with a $42.5 million Series B financing led by Perceptive Advisors, a prominent New York-based healthcare investment group, and Biogen, a leading biotechnology company. In parallel, we have built a world-class company, bringing in a team of experts in the various aspects of drug development.  We also put together one of the finest Scientific Advisory Boards in the industry, with the expertise and experience to guide us to success. 

With our strong financial foundation and through the dedication of our team and network of collaborators, we hope to begin clinical trials for our lead micro-dystrophin gene therapy candidate in 2017. In addition, we continue to build a robust pipeline of candidates that address other important factors – symptoms and physical mobility – thus implementing our 360-degree approach to tackling Duchenne muscular dystrophy. By encompassing all of the right pieces and constantly evaluating additional and newer platforms, modalities and technologies, we are doing our best to develop and advance meaningful interventions that benefit the entire DMD community.  

My wife Annie and I understand firsthand the needs of families affected by Duchenne muscular dystrophy in their everyday lives. Each of our programs is designed specifically to help every patient overcome the unique obstacles of this terrible disease.

Many of you have already contributed to these efforts, for which we are truly grateful. It is your feedback, bravery and drive that keep our team focused every day, and our commitment to you is that we will not waver until we get this done.

We will be providing regular updates on our progress as part of our commitment to open and transparent communication. In the meantime, I encourage you to visit our new website to see our latest news and find out more about our progress.


Ilan Ganot

Solid’s Founder & CEO

Related news


Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET


- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -


Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


More information about Solid?

Please subscribe to receive our latest news